Jun 11, 2026 · 26 min · 13 segments
ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302 - daraxonrasib and its standing ovation 2. MajesTEC-9 - 2L teclistamab in multiple myeloma in…
John BazarHost
The drug company, which is a company that does not yet have a drug that's FDA approved to my knowledge from looking at the website.
This looks to be their first chemical entity that maybe has been submitted to FDA.
talked about the FDA authorized the pathway for expanded access, where you can basically do N of 1 studies very quickly to get people on an experimental drug, because the FDA sees an obvious benefit for patients to get this drug, even though it's not FDA approved yet.
Because it improved overall survival by, you know, an absolute difference of about six months compared to chemotherapy.
So just as a refresher, since this is so big, it's about 500 people in resolute 302.
And they were randomized in a second-line setting of metastatic pancreatic cancer into either the RAS inhibitor, the on-RAS inhibitor, the Rax-on-RASib, or physician's choice of chemo.
Now, 40% of these folks had already received modified fulfirinox or fulfirinox in the first-line setting.
The drug company, which is a company that does not yet have a drug that's FDA approved to my knowledge from looking at the website.
This looks to be their first chemical entity that maybe has been submitted to FDA.
talked about the FDA authorized the pathway for expanded access, where you can basically do N of 1 studies very quickly to get people on an experimental drug, because the FDA sees an obvious benefit for patients to get this drug, even though it's not FDA approved yet.
Because it improved overall survival by, you know, an absolute difference of about six months compared to chemotherapy.
So just as a refresher, since this is so big, it's about 500 people in resolute 302.
And they were randomized in a second-line setting of metastatic pancreatic cancer into either the RAS inhibitor, the on-RAS inhibitor, the Rax-on-RASib, or physician's choice of chemo.
Now, 40% of these folks had already received modified fulfirinox or fulfirinox in the first-line setting.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.